Staining the tumour tissue obtained from the primary laparotomy with HIF 1a antibodies could result in grouping them in positive or negative as in our study, HIF 1a positive patients could enter clinical trials using a number of agents that inhibit HIF-1α accumulation including topotecan [26], 2-methoxyestradiol [27,28] and the Hsp90 inhibitors [29,30]. The gene discussed is HIF1A; the disease is neoplasm.